LBH589 (panobinostat) has been demonstrated to induce tumour shrinkage and sustain stable disease status in patients with small‐cell lung cancer.6 We propose that a combination therapy with HDAC inhibitors will open a new era for chemotherapeutic regimens of NSCLC to enhance efficacy and reduce drug resistance. Here, HDAC9 is linked to non-small cell lung carcinoma.